Actuate Therapeutics Inc
ACTUNASDAQHealthcare● Active
$1.82
$-0.06(-3.19%)
Market Cap$43545051
P/E Ratio—
52W High$9.35
52W Low$1.58
Actuate Therapeutics Inc (ACTU) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACTU · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.24
Est. -$0.23 · -4.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
ACTU reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.21 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.23 | -$0.24 | -4.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.24 | -$0.18 | +25.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.27 | -$0.25 | +7.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.19 | -$0.30 | -57.9% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.30 | -$0.32 | -6.7% | — | — | — |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$0.29 | -$0.33 | -13.8% | — | — | — |
| — Q4 FY2024 | Nov 13, 2024 | -$0.55 | -$0.55 | +0.0% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.21
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.24
EPS Est.
-$0.23
EPS Surpr.
-4.3%
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.24
EPS Surpr.
+25.0%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.27
EPS Surpr.
+7.4%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.19
EPS Surpr.
-57.9%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.30
EPS Surpr.
-6.7%
Revenue
—
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$0.33
EPS Est.
-$0.29
EPS Surpr.
-13.8%
Revenue
—
Q4 FY2024
Nov 13, 2024
EPS Actual
-$0.55
EPS Est.
-$0.55
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q2 FY2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q1 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q4 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2026 | $-0.19 | $-0.19 | $-0.19 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -4.3% | $2.97 | $2.90 | -2.36% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +25.0% | $2.32 | $2.27 | -2.16% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +7.4% | $6.30 | $5.88 | -6.67% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -57.9% | $8.53 | $8.22 | -3.63% |
| ▼ Q2 FY2025 | May 15, 2025 | -6.7% | $9.65 | $9.76 | +1.14% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -13.8% | $7.51 | $7.45 | -0.80% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +0.0% | $9.02 | $8.56 | -5.10% |
| — Q3 FY2024 | Sep 24, 2024 | — | $6.66 | $6.52 | -2.10% |
Q2 FY2026-2.36%
Report Date
May 14, 2026
EPS Beat/Miss
-4.3%
Price Before
$2.97
Price After
$2.90
Q1 FY2026-2.16%
Report Date
Mar 26, 2026
EPS Beat/Miss
+25.0%
Price Before
$2.32
Price After
$2.27
Q4 FY2025-6.67%
Report Date
Nov 13, 2025
EPS Beat/Miss
+7.4%
Price Before
$6.30
Price After
$5.88
Q3 FY2025-3.63%
Report Date
Aug 14, 2025
EPS Beat/Miss
-57.9%
Price Before
$8.53
Price After
$8.22
Q2 FY2025+1.14%
Report Date
May 15, 2025
EPS Beat/Miss
-6.7%
Price Before
$9.65
Price After
$9.76
Q1 FY2025-0.80%
Report Date
Mar 13, 2025
EPS Beat/Miss
-13.8%
Price Before
$7.51
Price After
$7.45
Q4 FY2024-5.10%
Report Date
Nov 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$9.02
Price After
$8.56
Q3 FY2024-2.10%
Report Date
Sep 24, 2024
EPS Beat/Miss
—
Price Before
$6.66
Price After
$6.52
Avg Beat Reaction-4.64%
Avg Miss Reaction-1.41%
Beat Rate3 / 8 quarters
Largest Move-6.67% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACTU ends December
Actuate Therapeutics Inc (ACTU) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.24 — missing the analyst consensus of $-0.23 by -4.3%. The next ACTU earnings date is expected around September 1, 2026.
Each quarter, investors track ACTU earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACTU revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACTU's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACTU earnings · 5 questionsActuate Therapeutics Inc's next earnings report is expected around September 1, 2026. ACTU typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACTU historically reports after market close (AMC).
ACTU earnings datewhen is ACTU earningsACTU next earnings datewhen does ACTU report earningsACTU earnings calendar
▸ Source: FMP · Actuate Therapeutics Inc SEC filings · US GAAP · Actuate Therapeutics Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026